25 December 2024NewsAmericasAndrew Wells, Partner & Head of Chemistry at HGF

WATCH: The new EU Clinical Trials Regulation – IP considerations

Andrew Wells of HGF explores how the EU Clinical Trials Regulation is affecting lifecycle IP strategies, and offers guidance on protecting inventions arising during clinical development.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

CureVac targets Moderna with 10-patent suit over Spikevax

28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.

Americas

Amneal acquires biopharma ahead of $300bn patent wave

23 April 2026 The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.

Americas

Health tech firm sues Nvidia-backed rival over ‘brazen’ theft

23 April 2026 Plaintiff alleges that a $6 billion rival probed its records system via a long-term customer, using confidential information to develop its product in the behavioural health tech space.

More features

Blow for Masimo’s fight with Apple as case against US Customs dismissed

Ligand buys biotech in $739m cash deal with litigation sweetener

CureVac targets Moderna with 10-patent suit over Spikevax

Safeguarding critical IP in a high-risk era: WIPR Trade Secrets West 2026

EU court under pressure to define SPC limits in patent row

Amneal acquires biopharma ahead of $300bn patent wave

Health tech firm sues Nvidia-backed rival over ‘brazen’ theft

Squires refuses to resurrect HydraFacial patent review

WATCH: The new EU Clinical Trials Regulation – IP considerations

More on this story

Editor's picks

Editor's picks

More features